New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:53 EDTMYL, VRX, ENDP, PRGOPullback has created attractive pharma opportunities, says JPMorgan
JPMorgan believes nothing has fundamentally changed to warrant the recent pullback in the specialty pharmaceutical space and views the pullback as an attractive buying opportunity. JPMorgan named Endo Health (ENDP), Mylan (MYL), Perrigo (PRGO), and Valeant (VRX) as stocks on which it maintains Overweight ratings, citing their favorable positions given the wave of consolidation ongoing in the industry.
News For ENDP;MYL;PRGO;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 30, 2015
10:24 EDTMYLMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
09:27 EDTMYLOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTMYLTeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTMYL, VRXMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
06:34 EDTMYLMylan files to sell 35M shares of stock for Abbott Laboratories subsidiaries
Subscribe for More Information
March 27, 2015
11:33 EDTPRGOPerrigo management to meet with Jefferies
Subscribe for More Information
07:45 EDTMYL, PRGOFDA to hold a public meeting
Subscribe for More Information
07:25 EDTVRX, MYLTeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
March 26, 2015
10:45 EDTVRXSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
07:30 EDTPRGO, ENDPDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 25, 2015
12:58 EDTVRX, ENDPPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
11:59 EDTVRXPershing Square reports 5.7% stake in Valeant, will continue talks
Pershing Square expects to conduct discussions with Valeant and other relevant parties regarding strategic acquisitions by or joint ventures with the company, or other similar arrangements. These discussions would be exploratory in nature and there is no assurance that they would lead to a definitive transaction.
07:12 EDTENDPAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 24, 2015
13:24 EDTVRXContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
March 23, 2015
10:00 EDTPRGOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:51 EDTVRXValeant price target raised to $240 from $185 at Susquehanna
Susquehanna raised its price target on Valeant to $240 from $185 to reflect the addition of durable assets and the improved growth trajectory its recent deals brings to its U.S. business. Susquehanna reiterated its Positive rating on Valeant shares.
07:17 EDTVRXAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
06:25 EDTPRGOPerrigo downgraded to Sector Perform from Outperform at RBC Capital
March 20, 2015
16:33 EDTVRX, ENDPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
15:31 EDTENDPEndo management to meet with Sterne Agee
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use